Massachusetts based Shire Pharmaceuticals has denied access to a life-saving drug required by a Chicagoland area child. 6-year-old Jack Fowler suffers from MPS II (Hunter Syndrome) and requires the life-saving treatment immediately in order to halt further progression of his devastating disease. The Fowler family appealed to the pharmaceutical company to provide pre-approval access to the investigational drug under the FDA’s expanded-access guidelines. Shire has made the decision to withhold treatment for Jack, even though a physician is ready to provide the treatment and funding has been made available to ensure baseline safety data is collected and ongoing efficacy is monitored. Without access to the therapy, Fowler faces certain death.
This is historical material “frozen in time”. The website is no longer updated and links to external websites and some internal pages may not work.
